Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025
Revolution Medicines (Nasdaq: RVMD), a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers, will release its Q2 2025 financial results on August 6, 2025, after market close.
The company's senior management will host a webcast at 4:30 p.m. ET (1:30 p.m. PT) to discuss quarterly results and provide corporate updates. The webcast will be accessible through the company's investor relations website, with a replay available for at least 14 days following the live presentation.
Revolution Medicines (Nasdaq: RVMD), un'azienda oncologica in fase avanzata specializzata nello sviluppo di terapie mirate per i tumori dipendenti da RAS, pubblicher脿 i suoi risultati finanziari del secondo trimestre 2025 il 6 agosto 2025, dopo la chiusura dei mercati.
Il management senior dell'azienda terr脿 una webcast alle 16:30 ET (13:30 PT) per discutere i risultati trimestrali e fornire aggiornamenti aziendali. La trasmissione sar脿 disponibile sul sito web delle relazioni con gli investitori dell'azienda, con una replica accessibile per almeno 14 giorni dopo la presentazione in diretta.
Revolution Medicines (Nasdaq: RVMD), una empresa oncol贸gica en fase avanzada centrada en desarrollar terapias dirigidas para c谩nceres dependientes de RAS, publicar谩 sus resultados financieros del segundo trimestre de 2025 el 6 de agosto de 2025, despu茅s del cierre del mercado.
La alta direcci贸n de la empresa realizar谩 una transmisi贸n en vivo a las 4:30 p.m. ET (1:30 p.m. PT) para comentar los resultados trimestrales y ofrecer actualizaciones corporativas. La transmisi贸n estar谩 disponible en el sitio web de relaciones con inversionistas de la empresa, con una repetici贸n accesible durante al menos 14 d铆as despu茅s de la presentaci贸n en vivo.
Revolution Medicines (雮橃姢雼�: RVMD)電� RAS 鞚橃〈靹� 鞎旍潉 雽�靸侅溂搿� 頃� 響滌爜 旃橂鞝� 臧滊皽鞐� 欤茧牓頃橂姅 頉勱赴 鞛勳儊 雼硠鞚� 膦呾枒頃� 須岇偓搿�, 2025雲� 2攵勱赴 鞛 瓴瓣臣毳� 2025雲� 8鞗� 6鞚� 鞛� 毵堦皭 頉勳棎 氚滍憸頃� 鞓堨爼鞛呺媹雼�.
須岇偓鞚� 瓿犾渼 瓴届榿歆勳潃 攵勱赴 鞁れ爜瓿� 旮办梾 鞐呺嵃鞚错姼毳� 雲检潣頃橁赴 鞙勴暣 霃欕秬鞁滉皠 旮办 鞓ろ泟 4鞁� 30攵� (韮滍弶鞏戩嫓臧� 鞓ろ泟 1鞁� 30攵�)鞐� 鞗轨簮鞀ろ姼毳� 歆勴枆頃╇媹雼�. 鞗轨簮鞀ろ姼電� 須岇偓 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼毳� 韱淀暣 鞝戩啀 臧�電ロ晿氅�, 靸濎瓿� 頉� 斓滌唽 14鞚缄皠 雼れ嫓氤搓赴臧� 鞝滉车霅╇媹雼�.
Revolution Medicines (Nasdaq : RVMD), une soci茅t茅 d'oncologie en phase avanc茅e sp茅cialis茅e dans le d茅veloppement de th茅rapies cibl茅es pour les cancers d茅pendants de RAS, publiera ses r茅sultats financiers du deuxi猫me trimestre 2025 le 6 ao没t 2025, apr猫s la cl么ture du march茅.
La haute direction de l'entreprise animera une webdiffusion 脿 16h30 ET (13h30 PT) pour discuter des r茅sultats trimestriels et fournir des mises 脿 jour corporatives. La webdiffusion sera accessible via le site des relations investisseurs de la soci茅t茅, avec une rediffusion disponible pendant au moins 14 jours apr猫s la pr茅sentation en direct.
Revolution Medicines (Nasdaq: RVMD), ein Unternehmen in der sp盲ten klinischen Phase, das sich auf die Entwicklung zielgerichteter Therapien f眉r RAS-abh盲ngige Krebsarten spezialisiert hat, wird seine Finanzergebnisse f眉r das 2. Quartal 2025 am 6. August 2025 nach B枚rsenschluss ver枚ffentlichen.
Das obere Management des Unternehmens wird um 16:30 Uhr ET (13:30 Uhr PT) eine Webkonferenz abhalten, um die Quartalsergebnisse zu besprechen und Unternehmensupdates zu geben. Die Webkonferenz ist 眉ber die Investor-Relations-Website des Unternehmens zug盲nglich, und eine Aufzeichnung wird mindestens 14 Tage nach der Live-Pr盲sentation verf眉gbar sein.
- None.
- None.
REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the second quarter of 2025 on Wednesday, August 6, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines鈥� senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.
To listen to the live webcast, or access the archived webcast, please visit:聽. Following the live webcast, a replay will be available on the company鈥檚 website for at least 14 days.
About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company鈥檚 R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company鈥檚 RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. The company anticipates that RMC-5127, a RAS(ON) G12V-selective inhibitor, will be its next RAS(ON) inhibitor to enter clinical development. Additional development opportunities in the company鈥檚 pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit and follow us on .
Revolution Medicines Media & Investor Contact:
[email protected]
[email protected]
FAQ
When will Revolution Medicines (RVMD) report Q2 2025 earnings?
What time is Revolution Medicines' (RVMD) Q2 2025 earnings call?
How can I access Revolution Medicines' (RVMD) Q2 2025 earnings webcast?
What type of cancer treatments is Revolution Medicines (RVMD) developing?
